

Update on Supply Status of Lanreotide and Ordering Guidance

Cipla is committed to providing timely updates regarding the supply status of Lanreotide Injection and to reaffirming our commitment to ensuring uninterrupted patient care.

Current Supply Situation

Following a recent FDA inspection at our contract manufacturing partner's facility, production of Lanreotide has been temporarily paused as remediation activities are ongoing. Re-supply of Lanreotide is expected to resume mid-year 2026.

Until manufacturing restarts, market supply of Lanreotide Injection will remain limited, and we anticipate ongoing variability in fulfillment timing.

Product Availability and Ordering Information

Given the temporary constraint, we encourage our customers to take the following steps to remain in the fulfillment queue:

- Submit drop-ship requests through your wholesaler to ensure proper order positioning as inventory becomes available. DSCSA statutory requirements apply
- Cipla will closely monitor supply levels and will fulfil orders as product becomes available

We recognize the importance of uninterrupted access to therapy for patients who depend on it. During this temporary constraint, in alignment with prescriber judgment, we encourage consideration of alternative treatment options to support patient continuity of care.

Cipla remains deeply committed to restoring stable, reliable supply of Lanreotide Injection as expeditiously as possible. Through this period, we will provide clear consistent updates and stand by patients who rely on this therapy.

Contact Information

For questions, order status updates, or additional support, please contact our Customer Service team at: Cipla.CS@cipla.com